Improved understanding of the immune system and its role in cancer development and
progression has led to impressive advances in the field of cancer immunotherapy over the …

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
for Bladder Cancer focuses on the clinical presentation and workup of suspected bladder …

Background Overall risks of hepatotoxicity with immune checkpoint inhibitors (ICIs) have yet
to be compared in primary liver cancers to other solid tumors. Methods We reviewed data …

Background Immune checkpoint inhibitors (ICIs) represent an appealing treatment for
patients with advanced urothelial cancer (aUC) and a poor performance status (PS) …

Background Few studies have investigated the safety and efficacy of anti-PD-(L) 1
antibodies in metastatic urothelial carcinoma (mUC) in daily clinical practice. Knowledge …

Background The benefits of pembrolizumab in patients with advanced urothelial carcinoma
(UC) and impaired performance status (PS) remain unknown. This study assessed the safety …

Tumors arising in the context of Lynch Syndrome or constitutional mismatch repair
deficiency are hypermutated and have a good response towards immune-checkpoint …

Background: We conducted this meta-analysis and systematic literature review to study the
ability of PD-L1 to predict objective response in patients with urothelial cancer treated with …

Background Atezolizumab (ATZ) has demonstrated antitumor activity and manageable
safety in previous studies in patients with locally advanced or metastatic platinum-resistant …

We performed a systematic review and meta-analysis on the response rates of patients with
treatment-refractory urothelial carcinoma treated with programmed cell death 1 (PD-1) and …